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Background: Tracheostomy mechanical ventilation (TMV) is performed in amyotrophic lateral sclerosis (ALS)
patients with a respiratory failure or when the non-invasive ventilation (NIV) is no longer effective. We
evaluated the clinical characteristics and survival of a cohort of tracheostomized ALS patients, followed in a
single ALS Clinical Center.
Methods: Between 2001 and 2010, 87 out of 279 ALS patients were submitted to TMV. Onset was spinal in 62
and bulbar in 25. After tracheostomy, most patients were followed up through telephone interviews to
caregivers. A complete survival analysis could be performed in ﬁfty-two TMV patients.
Results: 31.3% ALS patients underwent tracheostomy, with a male prevalence (M/F=1.69) and a median age
of 61 years (interquartile range=47–66). After tracheostomy, nearly all patients were under home care.
TMV ALS patients were more likely than non-tracheostomized (NT) patients to be implanted with a PEG de-
vice, although the bulbar-/spinal-onset ratio did not differ between the two groups. Kaplan–Meyer analysis
showed that tracheostomy increases median survival (TMV, 47 months vs NT, 31 months, p=0.008), with
the greatest effect in patients younger than 60 at onset (TMV≤60 years, 57.5 months vs NT≤60 years,
38.5 months, p=0.002).
Conclusions: TMV is increasingly performed in ALS patients. Nearly all TMV patients live at home and most of
them are fed through a PEG device. Survival after tracheostomy is generally increased, with the stronger
effect in patients younger than 60. This survival advantage is apparently lost when TMV is performed in
patients older than 60. The results of this study might be useful for the decision-making process of patients
and their families about this advanced palliative care.
© 2012 Published by Elsevier B.V.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disor-
der leading to a progressive motor neuron loss of function and
death, with the affected patients showing a wide spectrum of signs
and symptoms, such as limb paresis and muscle atrophy, dysphagia,
dysarthria, and loss of respiratory function [1].
Although in the last years the intensive management of ALS has im-
proved the patients' quality of life and survival [2–6], in most cases the
natural course of the disease still ends within 3–5 years from the onset
[7,8]. The leading cause of death is respiratory failure [8].
When respiratory failure becomes too severe to be managed by
non invasive ventilation (NIV) and/or when airway mucus accumula-
tion can no longer be cleared with common methods (e.g., symptom-
atic drugs, respiratory physical therapy, cough-assist machine), a
tracheostomy and subsequent invasive mechanical ventilation
(TMV) can be performed [9,10].
It has been suggested that TMV can prolong survival for patients
with advanced ALS [10–13]. However, the median survival after tra-
cheostomy differs among studies, ranging from about 8 months up
to about 3 years [11–13]. Several factors have been suggested to af-
fect survival in TMV ALS patients: age at onset (younger patients
may survive longer), the severity of motor disability (higher scores
at ALSFRS are predictive of longer survival), or cultural variables
[12–14].
After tracheostomy, most European and American ALS patients are
discharged home or to long-term care facilities, whereas more than a
half of Japanese patients live in hospital [11–13,15,16].
Only a minority of ALS patients from western countries (up to
10.6% in a single study [12]) are reported to undergo tracheostomy
[12,17,18]. This ﬁgure rises to up to 30% in a recent Japanese study,
suggesting a cross-cultural difference for the advanced management
of these patients [11]. Furthermore, a few studies suggest that trache-
ostomy may have a good acceptance rate, even when performed
without being discussed in advance [13,15]. There is, however, no
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sufﬁcient information on the disease progression in tracheostomized
patients. The Appel ALS rating scale (AARS) and the widely-used re-
vised version of the ALS functional rating scale (ALSFRS-R) tend to
ﬂatten in the advanced stages of the disease [19,20].
This work was undertaken to assess the demographic and clinical
characteristics of a cohort of ALS patients followed-up at a single ter-
tiary center who underwent TMV over a 10-year period. We evaluat-
ed the variables that may affect the risk of tracheostomy and the
survival rate.
2. Patients and methods
The study protocol was approved by the internal Ethics Commit-
tee of the Department of Experimental Biomedicine and Clinical Neu-
rosciences, University of Palermo, Italy.
2.1. Patients
Between 2001 and 2010, 279 sporadic (n=265) and familial (n=
14) ALS patients (M/F=1.29) were prospectively followed-up until
death or tracheostomy in a single tertiary ALS referral Center in Paler-
mo, Italy. All patients met the diagnostic criteria for possible, probable
or deﬁnite ALS, according to the EL Escorial/WFN revised criteria [21].
Patients with a clinical diagnosis of suspected ALS, Primary Lateral
Sclerosis and Progressive Muscular Atrophy were excluded from this
study. ALS patients (either sporadic or familial) with frontotemporal
dementia were also excluded. Ninety-two percent of our entire
ALS cohort took regularly riluzole (100 mg/day) until death or
tracheostomy.
192 patients (M/F=1.16) died without being submitted to TMV.
The main cause of death was respiratory failure (data on the causes
of death of a large fraction of these patients have been recently pub-
lished) [8]. 87 patients (M/F=1.69) underwent TMV, and in 40.3% it
was the result of an advance directive. Tracheostomies were
performed as surgical procedure in an ICU.
After tracheostomy, most patients were followed up through peri-
odic telephone contacts [22]. In a minority of cases (11.6%) we
performed home visits. After tracheostomy, the percentage of pa-
tients still taking riluzole dropped to 74.7%. Respiratory and general
management was provided to the TMV patients by periodic
re-admissions in the respiratory ICU or at their home through the
home care plan of the Italian Health Care System.
2.2. Methods
Demographic and clinical information, laboratory, neurophysio-
logical and imaging data were recorded for all patients in the two
groups (i.e. patients who underwent TMV or not). To this purpose
we used an electronic database (Access Microsoft® Corp., Redmond,
WA, USA).
Patients were submitted to follow-up visits by our multi- and
trans-disciplinary team in the ALS Clinic every 3–4 months to moni-
tor the clinical progression, the respiratory and swallowing functions
and the cognitive and psychological status. Seated erect Forced Vital
Capacity (FVC), nocturnal oxymetry and blood gas analysis were
used as indexes of respiratory function, whereas the severity of dys-
phagia was evaluated through the one-hundred milliliter water swal-
low test [3]. When necessary, a PEG device was placed and/or a NIV
was initiated [3,23], according to standard management procedures
[24]. Disease progression was evaluated through two clinimetric rat-
ing scales: i) the Appel ALS Rating Scale (AARS) and ii) the revised
ALS functional rating scale (ALSFRS-R) [19,20]. Based on a gain of n
points per month (ΔAARS), AARS allows identiﬁcation of at least
three different rates of progression, i.e. slow (gain: 0–2 points/
month), intermediate (gain: 2–4 points/month) and rapid (gain: >4
points/month) [19]. Disease progression was also measured through
an ALSFRS-R rate calculated as: ΔFS=(ALSFRS-R at onset−ALSFRS-R
at time of diagnosis)/diagnostic delay (months) [25]. According to
the ΔFS, three rates of progression could be calculated, i.e. slow
(ΔFSb0.5), intermediate (ΔFS 0.5–1), and rapid (ΔFS≥1) [25].
2.2.1. Data analysis and statistics
All analyses were made using SIGMASTAT and SPSS 17 software
packages. Variables were expressed as median with interquartile
ranges (IQR). Non parametric data comparisons were performed
using Mann–Whitney rank sum test. Correlations were studied with
the Spearman's test. Differences between groups were evaluated
using the chi-square test or, where appropriate, the Fisher exact
test. Survival data were expressed as median with IQR and analyses
were performed with the Kaplan–Meier method. Survival curves
were compared with the log-rank test. The Cox regression model
was utilized to verify whether age at onset was an independent pre-
dictor of survival in tracheostomized patients vs not tracheostomized.
Multivariate logistic regression analysis was performed to assess
which variables are likely to be associated with a risk of tracheosto-
my. Independent variables were: FVC at diagnosis and at the time of
Table 1
Clinical and demographic characteristics of the deceased (not tracheostomized) and the tracheostomized (deceased and not) ALS patients followed over a 10-year period
(2001–2010) in a single ALS Clinical Tertiary Center.
Variable Patients not tracheostomized (n=192) Patients tracheostomized (n=87)
Age at onset (years)
Median (range) 63 (55–71) 61 (47–66)
M/F 1.16 1.69
Site of onset
Spinal (n, %) 131 (68.2) 62 (71.2)
Bulbar (n. %) 61 (31.8) 25 (28.8)
Disease duration until death or tracheostomy (months)
Median (range) 31 (20–47) 35 (23–48)
Riluzole therapy (n, %) 175 (91) 65 (74.7)⁎
Patients with PEG (n, %) 62 (32.3) 57 (65.5)⁎⁎
Patients with NIV (≥4 h/day) before death or tracheostomy
(n, %) 85 (44.3) 37 (42.5)
Living conditions after tracheostomy
Under home care (%) NA 94.3
In hospital (%) NA 5.7
Tracheostomized vs not tracheostomized.
⁎ pb0.001 (Chi-square).
⁎⁎ p=0.0016, (Fisher's exact test).
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death/tracheostomy, rate of respiratory decline, as measured
by change of FVC/disease duration (months), ΔFS, age at onset, diag-
nostic delay (months) and survival. For all analyses, p-valuesb0.05
were considered signiﬁcant.
3. Results
3.1. Clinical and demographic characteristics of the TMV ALS patients
From 2001 through 2010, 279 ALS patients were followed at our
tertiary ALS Center until death or tracheostomy. Patients undergoing
tracheostomy (n=87, 31.3%) were further followed up with regular
telephone contacts (100%) and/or home visits (11.6%). The demograph-
ic and clinical characteristics of the deceased non-tracheotomized (NT)
ALS patients and those (both deceased andnot)whounderwent trache-
ostomy (TMV) are summarized in Table 1.
There was a male prevalence in the TMV patients (M/F: TMV, 1.69
vs NT, 1.16, p=ns), with no signiﬁcant difference in the age at onset
between the two groups. Furthermore, the proportion of spinal-onset
and bulbar-onset patients was comparable, the bulbar-onset patients
accounting for by some 30% in both groups. Although 92% of our en-
tire ALS cohort was regularly taking riluzole, this percentage dropped
to 74.7% after tracheostomy (pb0.001 TMV vs NT, chi-square). Sever-
al patients in fact autonomously stopped taking the drug after
tracheostomy.
TMV ALS patients were more likely to undergo to enteral feeding
than the NT patients. As shown in Table 1, two-third (n=57, 65.5%)
of the TMV ALS patients were fed by PEG as compared to 62 patients
(32.3%) in the NT group (p=0.001, Fisher's exact test). Note that
bulbar-onset patients, which invariably show early dysphagia and
difﬁculty to clear airway mucus, are not overrepresented in the TMV
group. Based on the swallowing test and, in some patients, the latest
BMI, there were in fact not more dysphagic patients among those
undergoing TMV (data not shown). We therefore suggest that a PEG
device is more likely to be implanted in patients undergoing trache-
ostomy, irrespective of the severity of the actual dysphagia.
After tracheostomy, over 92% of patients were on continuous ven-
tilation (i.e., more than 18 h per day) and 94.3% (n=82) lived under
home care.
We then assessed which variable is likely to be associated with the
risk of tracheostomy in our ALS cohort. As shown in Table 2, a multi-
variate logistic analysis suggested that both the rate of FVC decline
and the disease progression, as measured by ΔFS, correlate positively
with the risk of tracheostomy.
3.2. The disease progression and the tracheostomy
ALS is a heterogeneous disorder, with different rates of clinical pro-
gression. Patients may worsen rapidly or, conversely, the disease can
progress very slowly with a year-long natural history. Among the com-
monly used clinimetric rating scales, AARS reliably allows identiﬁcation
of three different rates of progression in ALS (i.e., slow, intermediate,
rapid) [19]. Two-thirds of the tracheostomized patients (59.8%)
showed an intermediate rate of progression, as compared to 41.2% of
NT. Slowly progressing patients were less likely to undergo tracheosto-
my (only 12.6%were submitted to this palliative care), whereas rapidly
evolving patients were more equally distributed among the two groups
(TMV, 27.6% vs NT, 33.8%). The difference among groups was found to
be signiﬁcant (p=0.009, chi-square analysis).
When the disease progression was calculated with ΔFS, we ob-
served a trend similar to that seen with ΔAARS. In particular, 20.7%
of the TMV patients showed a slow disease progression, as compared
with 30.4% of the NT; rapidly evolving patients were slightly overrep-
resented in the TMV group (i.e., 44.8% TMV vs 38.1% NT), while pa-
tients with an intermediate rate of progression were equally
distributed among the two groups (TMV, 34.5% vs NT, 31.5%). The dif-
ference between groups however did not reach signiﬁcance
(chi-square=2.95, DF 2, p=0.229). Although a low concordance be-
tween AARS and ALSFRS-R with disease progression has been
suggested [26], we found a signiﬁcant correlation between the two
rating scales, both in TMV and NT patients (TMV, r=0.41, p=
0.045; NT, r=0.27, p=0.005, Spearman Rank Order Correlation).
In conclusion, both ΔAARS and ΔFS suggest that slowly progressing
patients might be at a relatively lower risk for tracheostomy.
3.3. Survival
Among the TMV ALS patients, thirty-ﬁve were still alive at the
time of this study whereas the remaining ﬁfty-two patients (M/F=
1.73) were followed-up for their extended natural history, i.e. from
onset/diagnosis through tracheostomy until death. The age at onset
of this latter group was 62 years (IQR=53–67), with a median dis-
ease duration from onset to tracheostomy of 35 months (IQR=
23–48).
Fig. 1 shows the survival plot of the deceased TMV and the NT ALS
patients. As expected, the TMV prolonged survival, thus bringing pa-
tients well beyond their natural history of disease. Themedian surviv-
al from onset to death was 47 months (IQR=33–61) for TMV and
31 months (IQR=20–47) for non-tracheostomized patients (p=
0.008, log-rank test).
Thirteen TMV patients (25%, M/F=1.6) died within the ﬁrst
month following tracheostomy. Of these, 84% underwent tracheosto-
my as an emergency procedure, twelve had had a spinal onset and in
one patient onset was bulbar; the median age at disease onset was
64 years (IQR=61–71). These patients showed FVC values, at the
time of the surgical procedure, signiﬁcantly lower than the group
who survived longer (Table 3). Furthermore, by analyzing the whole
group of deceased TMV patients, we found that a low FVC before
Table 2
Multivariate analysis of tracheostomy risk in the ALS cohort.
Variable Odds ratio 95% CI p
Age at onset 0.99 0.96–1.02 0.43
Diagnostic delay 0.98 0.95–1.02 0.45
FVC at diagnosis 1.01 0.99–1.03 0.09
Last FVCa 1.08 0.96–1.19 0.035
Rate of FVC decline 1.28 0.99–1.40 0.05
Survivalb 1.01 0.98–1.03 0.39
ΔFS 1.37 0.97–1.95 0.07
a Before death or tracheostomy.
b Until death or tracheostomy.
Fig. 1. Kaplan–Meyer survival curve of the ALS patients who underwent tracheostomy
(continuous line; median survival [months] 47 [IQR=33–61]) and ALS patients that
died without being submitted to tracheostomy (broken line; median survival [months]
31 [IQR=20–47]). p=0.008, log-rank test.
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tracheostomy correlated positively with a shorter survival (n=52,
r=0.44, p=0.02, Spearman rank order analysis). Several factors, be-
sides the respiratory muscles weakness, are associated with a low FVC
in ALS patients, e.g., mouth muscles weakness, airway mucus accu-
mulation, etc. Although we could not ascertain all speciﬁc causes
leading to death in this group, it is likely that these patients were in
a poor clinical status. None among the TMV ALS patients died because
of a voluntary decision to come off the ventilation. On the other hand,
the Italian law ﬁrmly prohibits a patient to voluntarily stop a cure/
treatment, if this is leading to death.
Nineteen patients (36.5%, M/F=3.75) showed a survival after tra-
cheostomy longer than one year. 52.6% of patients in this group were
primarily bulbar, while the median age at disease onset was 54 years
(IQR=51–63).
We also analyzed the median survival of TMV ALS patients by
using 60 years as a cut-off age at onset. The Kaplan–Meyer analysis
shows that young patients were likely to survive longer after trache-
ostomy (Fig. 2). The median survival was 57.5 months (IQR=46–70)
in patients younger than 60, whereas it was 38.5 months (IQR=30–
49) in the older group (pb0.01, log-rank test). The Cox proportional
hazards model conﬁrmed that lower age at onset is associated with
survival in TMV patients (chi-square, 23.31, DF 1, p=0.00).
4. Discussion
This work is a clinical and survival analysis of a relatively large co-
hort of ALS patients submitted to TMV and followed-up over a de-
cade, from 2001 to 2010. All patients were followed-up in a single
tertiary ALS Center in Palermo, Italy. Tracheostomy was performed
in some 30% of the whole ALS population, with a slightly higher prev-
alence in men. Tracheostomy signiﬁcantly prolonged survival, with
the stronger effect on patients younger at onset (i.e., less than 60).
TMV is an opportunity for patients with advanced ALS and respira-
tory failure that up to the recent past have been seldom offered by
neurologists in Europe and North America [27]. TMV may prolong
survival in ALS patients and it is now included in the current manage-
ment guidelines [24,28]. Besides this evidence, tracheostomy rate in
ALS patients is still relatively low in most Western countries
[12,17,18,29,30], dropping to less than 2% in two reports [17,29]. Con-
versely, a nationwide study in Japan suggests that at least in that
country up to 30% of ALS patients undergo TMV [11].
We showed that nearly one‐third of the ALS patients underwent
tracheostomy, a proportion deﬁnitively higher than that published
in most Western countries. While cultural and religious factors
could in part play a role, we suggest that being regularly followed in
a tertiary referral ALS Center may be a key variable affecting the rela-
tively high number of tracheostomies observed. Tertiary ALS Centers
deﬁnitely have a positive impact on the disease management, provid-
ing continuous information and education on the disease. A few stud-
ies have suggested, in fact, that being followed by ALS Centers
increases survival [5,6]. Furthermore, improved knowledge about
the disease, the dissemination of information through media and
TV, and increased resource availability by the Italian Local Health
System might also have contributed substantially to the increasing
number of tracheostomies.
With regard to sex, in our ALS cohort men were more likely than
women to undergo tracheostomy (M/F=1.69). A similar ratio
(i.e., M/F=1.73) has been reported in a recent population-based
study [12]. Other studies show a higher male-to-female proportion
among TMV patients, peaking to 2.55 in a Scandinavian survey
[15,31]. The male prevalence in TMV ALS was instead not conﬁrmed
in a Spanish study, where the M/F ratio was 0.72 [10]. The interpreta-
tion is that invasive mechanical ventilation is generally underutilized
by women. Men may be favored because they have a higher income
and/or longer education. In addition, we have preliminary data
suggesting a proneness to caregiving in female spouses, which
might further favor the use of complex palliative care procedures in
men (Spataro R, in preparation). The higher education we found in
TMV ALS patients (TMV, median 8 years [IQR=5–13] vs NT, median
5 years [IQR=5–8], p=0.008) is an indication that also this variable
may actually play a role in the propensity to undergo to tracheosto-
my. An indirect support to this hypothesis comes from another
study which showed that education in TMV ALS patients was higher
than controls [13].
Disease progression in ALS is highly variable, froma slow course, over
years, to a very rapid evolution from onset to death/tracheostomy. We
found that, according to AARS and ALSFRS-R, tracheostomy was more
likely to be performed in patients with an intermediate and rapid clinical
progression. This is in line with the results of a multivariate analysis
which showed that the rate of FVC declined and disease progression is
positively associated with a risk to being tracheostomized. Tracheosto-
mies were instead relatively few in the slowly progressing patients,
supporting the notion that in this group the development of a severe re-
spiratory failure is an uncommon event [20].
It is known that tracheostomy signiﬁcantly prolongs survival in
ALS bringing patients well beyond the natural history of the disease
[10,12,13]. If compared with the patients who died without being
tracheostomized, we found that those placed into an invasive me-
chanical ventilation survived a median time of 12 months longer.
However, less than 4% of our TMV ALS patients showed a survival lon-
ger than 4 years, and none was alive beyond 5 years. This is in line
with another study where it was shown that, among patients under-
going tracheostomy, those with ALS had the poorest long term surviv-
al, with only 5% alive at 5 years [16].
Thirteen out of the ﬁfty-two deceased TMV ALS patients died
within the ﬁrst month after tracheostomy. We found that a relatively
low FVC, either as air volumesmeasured or percent predicted, was as-
sociated to this very short survival. It is therefore suggested that a
possible optimal timing for tracheostomy, which might allow longer
survival, is when FVC is some 32% predicted and/or when the
Table 3
FVC variables related with a poor survival (≤1 month) in TMV ALS patients.
FVC variablea TMV survival (months) p
≤1 (n=13) >1 (n=41)
Liters, mean (SD) 0.67 (0.44) 1.34 (0.60) 0.001b
% predicted, median (range) 20 (18.5–26.5) 32 (22.5–39) 0.013c
a Last FVC values taken before tracheostomy.
b Student's t test.
c Mann–Whitney U test.
Fig. 2. Kaplan–Meyer survival curve of the TMV ALS patients with age at
onset≤60 years (continuous line; median survival [months] 57.5 [IQR=46–70])
vs>60 years (broken line; median survival [months] 38.5 [IQR=30–49]). p=0.002,
log-rank test.
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measured air volume is at least 1.3 l (Table 3). Although other vari-
ables might be implicated in the very short survival of this group of
TMV ALS patients, the very low FVC values seem to be an indicator
of a poor clinical status, thus making patients highly vulnerable.
Age is another variable who affected survival in our TMV ALS pop-
ulation. We showed that the median survival in TMV ALS patients
younger than 60 years was much longer than that of the over 60
group (12 months vs 3.5 months, respectively, p=0.024). Tracheos-
tomy does not seem to confer a signiﬁcant survival advantage in pa-
tients older than 60. It is known that being younger at disease onset
is associated with a longer natural history of the disease, and this
may in part reﬂect the longer survival after tracheostomy in the
under 60 group. If provided with advanced communicative instru-
ments and adequate devices and care to allow independence and
well-being, tracheostomy may become a good option in young
patients.
In conclusion, by analyzing a cohort of ALS patients followed over
a ten-year period in a single ALS Center, we show that tracheostomy
is increasingly performed. Nearly all TMV ALS patients live under
home care. Survival of ALS patients after tracheostomy is prolonged,
particularly in those younger than 60, and this probably will allow
more patients to proceed through this advanced palliative care in
the coming years. However, patients should be given full option to
decide, by signing advance directives, if and when to interrupt TMV,
should they wish so. Unfortunately, in several countries, included
Italy, the lack of advance directives represents a limit in making an
appropriate choice.
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